Dr. Michelle Lea Ramirez, DO

Dr. Ramirez practices at St Mary's Regional Medical Center - HOPD in Lewiston, Maine.

Dr. Ramirez's NPI, 1083876296, was assigned on June 29, 2008. Dr. Ramirez graduated from New York College of Osteo Medicine of New York Institute of Technology in 2007. Dr. Ramirez holds Rhode Island license CDO00756.

Dr. Ramirez's primary practice is St Mary's Regional Medical Center - HOPD, at 93 Campus Ave, Lewiston, ME 04240.

Dr. Ramirez's primary practice is St Mary's Regional Medical Center - HOPD in Lewiston, Maine. Dr. Ramirez is also affiliated with St. Mary's Regional Medical Center. The medical group on file is Select Physical Therapy. Dmand AI also links Dr. Ramirez to 3 more medical groups, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account. Dr. Ramirez's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramirez practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Ramirez's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Ramirez's licenses on file in 2 states: Rhode Island and Pennsylvania.

CMS data shows 67 Medicare services from Dr. Ramirez across 4 procedure codes in 2024, for 46 Medicare patients. Medicare paid $3,402 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 46 Medicare patients who saw Dr. Ramirez in 2024. The largest group is 65 to 74, with 15 patients. 74% of them have high cholesterol, and 70% have high blood pressure. 52% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramirez's median patient age at 68, with 40% women.

In 2024, Dr. Ramirez wrote 251 Medicare Part D claims for 104 patients. 95% of them were for generic drugs. CMS names the drug for 180 of them, across 10 drugs with 11 or more claims each, at $3,558 in total drug cost. In 2023, CMS named 106 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Ramirez for performance year 2024, reported through an alternative payment model (APM). Dr. Ramirez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Ramirez in 2012.

CMS Open Payments shows 183 general payments to Dr. Ramirez from 38 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 52% of the total. Intuitive Surgical, Inc. paid the most, $3,051.

Dr. Ramirez graduated from New York College of Osteo Medicine of New York Institute of Technology in 2007.